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Abstract
Background: Pandemic influenza vaccine manufacturing capacity and distribution agility is enhanced through the
availability of equivalent antigen-sparing vaccines. We evaluated equivalence in terms of immunogenicity between
GlaxoSmithKline Vaccines’ A/California/7/2009 (H1N1)v-like-AS03 vaccines manufactured in Dresden (D-Pan), and
Quebec (Q-Pan).
Methods: In two studies, 334 adults 18-60 years of age received 2 doses of D-Pan or Q-Pan containing 3.75 μg
haemagglutinin antigen (HA) adjuvanted with AS03A administered 21 days apart, and 209 children 3-9 years of age
received 1 reduced dose of D-Panor Q-Pan (0.9 μg HA) or Q-Pan (1.9 μg HA) with AS03B. Haemagglutination
inhibition (HI) titres were assessed before and 21 days post-vaccination. HI persistence was assessed after
12 months in adults and 6 months in children.
Results: Pre-defined criteria for immunological equivalence of Q-Pan versus D-Pan were achieved in both
populations. After one vaccine dose, ≥97.6% of adults and children had HI titres ≥1:40, with increases in
titre ≥25.7-fold. CHMP and CBER regulatory acceptance criteria for influenza vaccines were exceeded by all groups
in both studies at Day 21. In adults,the percentage with HI titres ≥1:40 at Month 12 was 82.9% (Q-Pan) and 84.0%
(D-Pan). In children, the percentages at Month 6 were 75.3.3% (Q-Pan0.9), 85.1% (D-Pan0.9) and 79.3% (Q-Pan1.9).
Safety profile of the study vaccines was consistent with previously published data.
Conclusion: Two studies indicate that A/California/7/2009 (H1N1)v-like HA manufactured at two sites and
combined with AS03 are equivalent in terms of immunogenicity in adults and children and highly immunogenic.
Different HA doses elicited an adequate immune response through 180 days post-vaccination in children 3-9 years
of age.
Trial registration: ClinicalTrials.gov: NCT00979407 and NCT01161160.
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Background
In June 2009 the World Health Organisation declared
the first influenza pandemic since the 1960s, caused by
A/California/7/2009 H1N1 influenza strain [1]. More
than 18,000 H1N1-related deaths were reported by July
2010, with infections reported in 214 countries world-
wide [2,3]. Vaccination is regarded as the most effective
intervention to prevent and attenuate influenza pan-
demics [4], and by the end of 2009, vaccines targeting
the pandemic A/California/7/2009 H1N1 strain had
been produced by several manufacturers.
Global influenza antigen manufacturing capacity is
limited, and the formulation of H1N1 vaccines with
oil-in-water adjuvants using reduced amounts of virus
antigen match or surpass immunogenicity compared to
unadjuvanted formulations allowing for an increased
number of doses from the available antigen bulk (anti-
gen sparing). GlaxoSmithKline Vaccines’ A/California/
7/2009 (H1N1)v-like vaccine contains the proprietary
Adjuvant System 03 (AS03) which allows a 4-fold re-
duction in the amount of haemagglutinin antigen (HA)
necessary to achieve an adequate immune response in
adults [5,6]. The A/H1N1/2009-AS03 influenza vaccine
has been demonstrated to be immunogenic, with a
clinically acceptable safety profile in adults, adolescents
and children [5-10]. A single dose of A/H1N1/2009-
AS03 was recommended for adults (3.75 μg HA). A
single dose containing half of the adult dose (1.9 μg
HA) was recommended for children 6 months to
10 years of age [11].
The A/H1N1/2009-AS03 vaccine was manufactured at
two sites: vaccine manufactured in Dresden is licensed
as Pandemrix™ (D-Pan), and vaccine manufactured in
Quebec is licensed as Arepanrix™ H1N1(Q-Pan), using
somewhat different methods of HA preparation. HA
for a pre-pandemic H5N1 vaccine manufactured at the
Dresden and Quebec sites was shown to be equivalent
in terms of immunological outcomes when adminis-
tered with AS03 to adults [12]. Demonstration of im-
munological equivalence between D-Pan and Q-Pan
H1N1 vaccines would provide reassurance on the com-
parability of both products, and would allow clinical
trial data and post-marketing effectiveness estimates to
be extrapolated between each product. We report the
results of two clinical studies conducted with D-Pan
and Q-Pan H1N1 vaccines that confirmed the equiva-
lence of the two vaccines in terms of immunogenicity
in adults and children, and assessed the feasibility of
further antigen sparing in children.
Methods
Study design
The adult study (113535, NCT00979407) was a Phase
III, randomised, controlled study conducted in 7 cen-
tres in Germany and France between 12 October 2009
and 4 November 2010. Healthy adults between 18 and
60 years of age were randomised (1:1) to receive 2 doses
of either D-Pan or Q-Pan (3.75 μg HA) adjuvanted with
AS03A administered 21 days apart (Table 1).
The study in children (114495, NCT01161160) was a
Phase II randomised, controlled study conducted in 2 cen-
tres in the Philippines and Thailand between 25 January
2010 and 31 January 2011. Healthy children 3 to <10 years
of age were randomised (13:13:10) to receive a single
dose of D-Pan or Q-Pan vaccine containing one half of
the recommended HA dose for children (0.9 μg HA
with AS03B): D-Pan0.9 group and Q-Pan0.9 group), or a
standard paediatric dose (1.9 μg HA with AS03B: Q-
Pan1.9 group, Table 1).
Both of the studies were observer-blind: that is, the
vaccinee and those responsible for the evaluation of any
study endpoint were unaware of which vaccine was
administered.
The studies were conducted according to good clinical
practice and in accordance with the Somerset West 1996
version of the Declaration of Helsinki. The protocol and as-
sociated documents were reviewed and approved by local
ethics committees: study in adults - in Germany: the Ethik-
Kommission der Sächsische Landesärztekammer, Ethik-
Kommission der Medizinischen Fakultät der Universität
Würzburg, Geschäftsstelle der Ethikkommissionan der
Universität Regensburg, and in France the Comité de
Protection des Personnes Ile de France I. Study in chil-
dren – The Royal Thai Army Medical Department
Table 1 Study design
Study Group Vaccine HA dose Schedule
Study in adults D-Pan A/California/7/2009 (H1N1)v-like + AS03A 3.75 μg 2 doses
18-60 year olds Q-Pan A/California/7/2009 (H1N1)v-like + AS03A 3.75 μg 2 doses
Study in children D-Pan0.9 A/California/7/2009 (H1N1)v-like + AS03B 0.9 μg 1 dose
3-9 year olds Q-Pan0.9 A/California/7/2009 (H1N1)v-like + AS03B 0.9 μg 1 dose
Q-Pan1.9 A/California/7/2009 (H1N1)v-like + AS03B 1.9 μg 1 dose
HA haemagglutinin antigen, AS03 an oil-in-water emulsion containing DL-α-tocopherol and squalene in an aqueous phase with the non-ionic detergent
polysorbate80. AS03A contains 11.86 mg DL-α-tocopherolper dose; AS03B contains 5.93 mg DL-α-tocopherol per dose.
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Figure 1 (See legend on next page.)
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Phramongkutklao Hospital in Thailand, and the Mary
Chiles General Hospital in the Philippines. Written in-
formed consent was obtained from subjects or the par-
ents/guardians of children before study procedures.
Study subjects
Adults were not eligible if they had clinical or con-
firmed influenza infection within 6 months prior to
study start, if they had a history of neurological disease
or Guillain-Barre syndrome, or if they had received any
non-study vaccine within 30 days of enrolment. Women
enrolled in the study were to agree to avoid pregnancy
for 2 months after the second dose. Children were not
included if they had a history of physician-confirmed
infection or previous vaccination against A/California/
7/2009 (H1N1)v-like virus. Other exclusion criteria in-
cluded receipt of any licensed live-attenuated vaccine
within 30 days before study vaccination, any licensed
inactivated vaccine within 15 days of study vaccination,
or planned administration of any other vaccine not
foreseen by the study protocol between Day 0 and Day
21. Routine childhood vaccinations were allowed dur-
ing the study, but were not to be administered on the
same day as the study vaccine.
In both studies subjects were not eligible to parti-
cipate if they had a diagnosis of cancer or had received
treatment for cancer in the last 3 years. Subjects were
not eligible if they were immunosuppressed from any
cause, including chronic (>14 days) intake of immu-
nosuppressants, if they had received blood products
within 3 months of the study, or if they had any dis-
order of coagulation.
Vaccines
The study vaccines were monovalent, split-virion, inac-
tivated influenza A (H1N1) 2009 vaccines (reassortant X-
179A strain derived from the A/California/7/2009 (H1N1)v
virus) prepared from virus propagated in the allantoic cavity
of embryonated hens’ eggs. The manufacturing processes
for the antigen component of D-Pan and Q-Pan H1N1
were similar to the manufacturing processes of their corre-
sponding licensed seasonal influenza vaccines (Fluarix™
and FluLaval™, respectively). For D-Pan H1N1, the virus
was purified by centrifugation and disrupted with sodium
deoxycholate. The virus was inactivated by sodium deoxy-
cholate and formaldehyde. The split virus was further
purified by ultrafiltration and sterilised by filtration.
For Q-Pan H1N1, the virus was treated with ultraviolet
light followed by formaldehyde inactivation. After
purification by centrifugation and disruption with so-
dium deoxycholate, the split virus was homogenised
and sterilised by filtration. All subjects received a speci-
fied volume of an antigen formulation with a concen-
tration of HA of 15 μg/ml mixed with AS03 (Table 1).
Immunogenicity assessment
Adults provided blood samples before and 21 days after
each vaccine dose, and again 6 months and 1 year after
the first dose. Blood samples were collected from chil-
dren prior to vaccination, and 21 days and 6 months
after vaccination. The humoral immune response to
vaccination was assessed by measuring antibody inhib-
ition of haemagglutination (HI) against the A/Califor-
nia/7/2009 (H1N1)v-like strainas previously described
[13]. The lowest dilution tested was 1:10. The titration end-
(See figure on previous page.)
Figure 1 Subject flow through the studies. (A) Study in adults: reasons for elimination from the ATP immunogenicity and persistence cohorts
were: non-compliance with vaccination/blood sampling schedule; blood sample not taken/insufficient quantity for any test; randomisation failure;
received a vaccine forbidden by the protocol. (B) Study in children: reasons for elimination from the ATP persistence cohort were: received
medication forbidden per protocol; blood sample not taken or quantity not sufficient for any test.
Table 2 Demographic characteristics: ATP immunogenicity cohorts at Day 21 in both studies
Characteristic Categories Study in adults Study in children
Q-Pan D-Pan Q-Pan0.9 D-Pan0.9 Q-Pan1.9
N 164 164 76 75 58
Age (years) Mean (SD) 39.7 (11.98) 40.1 (11.74) 6.0 (2.03) 6.0 (2.02) 6.0 (2.00)
Range 18-60 19-60 3-9 3-9 3-9
Gendern (%) Female 75 (45.7) 86 (52.4) 30 (39.5) 38 (50.7) 27 (46.6)
Male 89 (54.3) 78 (47.6) 46 (60.5) 37 (49.3) 31 (53.4)
Racen (%) African/African American 3 (1.8) 2 (1.2) 0 0 0
Central/South/East & Southeast Asian 0 0 76 (100) 75 (100) 56 (100)
Arabic/North African 3 (1.8) 0 0 0 0
Caucasian/European 158 (96.3) 162 (98.8) 0 0 0
N number in the specified cohort, n (%) number (percentage), SD standard deviation. See Table 1 for details of treatment groups in each study.
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point was the highest dilution step that showed complete
inhibition (100%) of haemagglutination. HI antibody titres
of ≥1:40 and were considered indicative of seroprotection
in adults [14,15].
Safety and reactogenicity assessment
In each study local and age-appropriate general symp-
toms were solicited and their occurrence were recorded
on diary cards for 7 days after each vaccine dose (day 0-
6). All other adverse events in adults were recorded
from study start until 63 days after the second dose. In
children all other adverse events were recorded for
42 days after vaccination. Serious adverse events (SAEs)
and potentially immune-mediated diseases (pIMDs)
were recorded throughout the duration of the studies:
for 12 months after the first dose in adults and for
6 months after vaccination in children.
Immunogenicity objectives
Study in adults
The primary objective of the adult study was to de-
monstrate equivalence between Dresden and Quebec-
manufactured A/California/7/2009 (H1N1)v-like vaccine
in terms of the HI geometric mean antibody titre
(GMT) ratio (D-Pan divided by Q-Pan) 21 days after
dose 1. Equivalence was demonstrated if the limits of
the 2-sided 95% confidence interval (CI) on the GMT
ratio were within the interval [0.5:2].
Secondary objectives included assessment of the equiva-
lence between groups in terms of HI GMTs 21 days after
dose 2, and in terms of seroconversion rate 21 days after
dose 1. Equivalence was demonstrated if the 2-sided 95%
CI on the GMT ratio (after dose 2) was within the interval
[0.5;2], and if the 2-sided 95% CI on the difference be-
tween groups in the seroconversion rate (defined below)
was within the interval [-10%;10%].
Study in children
The co-primary objectives of the study in children were
to demonstrate immunogenicity of the reduced antigen
content A/California/7/2009 (H1N1)v-like vaccines (Q-
Pan0.9 and D-Pan0.9 groups) in terms of Food and Drug
Administration Center for Biologics Evaluation and Re-
search (CBER) [16], and European Medicines Agency
Committee for Human Medicinal Products (CHMP)
[17], criteria for acceptable immunogenicity of pan-
demic influenza vaccines. Secondary objectives included
the demonstration of equivalence between Q-Pan0.9
and D-Pan0.9 in terms of HI antibody GMTs 21 days
after vaccination. Equivalence was demonstrated if the
2-sided 95% CI on the GMT ratio were within the inter-
val [0.5;2]. Immunogenicity of the Q-Pan1.9 vaccine
was also assessed.
Statistical methods
The primary immunogenicity analysis was done on the
according to protocol (ATP) immunogenicity cohorts at
each blood sampling time point. At each time point, the
ATP cohort included all evaluable subjects who met eli-
gibility criteria, who complied with the protocol-defined
procedures, who were not eliminated during the study
and for whom data concerning immunogenicity mea-
sures were available.
The GMT ratio and the 95% CIs were calculated using
a covariance (ANCOVA) model adjusted for age, pre-
vaccination antibody titre and pre-vaccination history
in adults, and for age and pre-vaccination antibody
titre in children.
The seroconversion rate was defined as the percent-
age of initially seronegative vaccinees (HI titre < 1:10)
with a post-vaccination titre ≥ 1:40; or the percentage of
initially seropositive vaccinees (HI titre ≥1:10) with at
least a 4-fold increase in the post-vaccination titre. The
Table 3 Results of the inferential analysis comparing groups in the study in adults and in children
(ATP immunogenicity cohorts)
Endpoint Criteria to meet the primary objectives Value (95% CI) Criteria met?
Study in adults
Anti-H1N1 GMTs 95% CI for ratio is within [0.5; 2] at Day 21 1.20 (0.96;1.49) Yes
95% CI for ratio is within [0.5; 2] at Day 42 0.9 (0.76; 1.06) Yes
Seroconversion rate 95% CI for the difference in within [-10; +10] at Day 21 3.66 (-0.82; 8.74) Yes
Study in children (each group)
CHMP Seroconversion rate >40% ≥98.7% for each group Yes
%(≥1:40) > 70% ≥98.3% for each group Yes
Seroconversion factor >2.5 ≥25.7 for each group Yes
CBER LL of the 95% CI on the seroconversion rate >40% ≥90.8 for each group Yes
LL of the 95% CI on the % ≥1:40 is >70% ≥ 90.8 for each group Yes
Anti-H1N1 GMTs 95% CI for ratio (Q-Pan0.9/D-Pan0.9) is within [0.5; 2] at Day 21 0.96 (0.73; 1.26) Yes
95% CI 95 percent confidence interval, LL lower limit of the 95% CI, GMT geometric mean antibody titre. See Table 1 for details of treatment groups in each study.
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seroconversion factor was defined as the geometric
mean of the post-vaccination titre divided by the pre-
vaccination titre.
With 144 evaluable subjects in each group and assum-
ing a standard deviation on the HI GMT of 0.65, the
adult study had 95.05% power to meet the primary ob-
jective of demonstrating equivalence.
With 180 evaluable subjects and assuming a seropro-
tection rate of 90%, a seroconversion rate of 80% and a
seroconversion factor of 20, the study in children had
94.6% power to meet the co-primary objectives of achiev-
ing CBER/CHMP criteria for D-Pan0.9 and Q-Pan0.9.
Analyses were performed using SAS® software version
9.2 (SAS Institute Inc., Cary, NC, United States) and
ProcStatXact 8.1.
Results
Study subjects
There were 334 subjects enrolled and vaccinated in the
adult study and 209 who were enrolled and vaccinated
in the study in children (Figure 1). Demographic charac-
teristics were comparable between groups in each study
(Table 2). No subject withdrew from the study due to an
adverse event.
Immunogenicity in adults
The primary and secondary objectives of the adult study
were met: the pre-defined criteria for equivalence of Q-
Pan and D-Pan vaccines were achieved at Day 21 and at
Day 42 (Table 3).
After a single vaccine dose, all subjects in both
groups were seropositive for HI antibodies and at least
97.6% had titres ≥1:40 (Table 4). HI antibody GMTs in-
creased by at least 32-fold after the first dose adminis-
tered to both groups. After dose 2, 100% of subjects
had titres ≥1:40 and HI antibody GMTs increased by
63-fold in each group. CHMP and CBER regulatory ac-
ceptance criteria for influenza vaccines were exceeded
by both groups at Day 21 and Day 42 (Table 4).
At Month 6 at least 96.8% of subjects in each group con-
tinued to have HI antibody titres ≥1:40 (Table 4). By Month
12, 82.9% of subjects in the Q-Pan group and 84.0% in the
D-Pan continued to have HI antibody titres ≥1:40. GMTs
reduced over time in both groups but remained higher at
Month 12 than pre-vaccination levels (Figure 2).
Immunogenicity in children
The primary and secondary objectives of the study in chil-
dren were met: CHMP and CBER regulatory acceptance
criteria for influenza vaccines were exceeded in both
groups at Day 21 (Table 3). Equivalence between the Q-
Pan0.9 and D-Pan0.9 groups was demonstrated in terms
of GMTs.
At day 21 after vaccination all subjects were seropositive
for HI antibodies and at least 98.3% of subjects in each
group had HI antibody titres ≥1:40 (Table 5). Compared
to pre-vaccination levels, GMTs at Day 21 increased by
25.7-fold in the Q-Pan0.9 group, 27.1-fold in the D-Pan0.9
group and 32.2-fold in the Q-Pan1.9 group.
At Month 6, 75.3% of subjects in the Q-Pan0.9 group,
85.1% in the D-Pan0.9 group and 79.3% in the Q-Pan1.9
group continued to have HI antibodies ≥1:40 (Table 5).
GMTs decreased over time in all groups but remained
higher than pre-vaccination levels (Figure 2).
Table 4 Study in adults: haemagglutinin inhibition (HI) antibodies to A/California/7/2009 (H1N1)v-like strain after
vaccination (ATP cohorts for immunogenicity and persistence)
Group Time N Seroconversion rate Seroconversion factor Seroprotection rate
point % (95% CI) Ratio (95% CI) %≥1:40 (95% CI)
Q-Pan Pre 164 - - - - 13.4 (8.6; 19.6)
Day 21 164 93.9 (89.1; 97.0) 32.0 (26.5; 38.6) 97.6 (93.9; 99.3)
Day 42 155 98.7 (95.4; 99.8) 63.2 (52.6; 75.9) 100 (97.6; 100)
Month 6 154 91.6 (86.0; 95.4) 21.7 (18.1; 25.9) 97.4 (93.5; 99.3)
Month 12 146 72.6 (64.6; 79.7) 11.0 (9.1; 13.3) 82.9 (75.8; 88.6)
D-Pan Pre 164 - - - - 11.6 (7.1; 17.5)
Day 21 164 97.6 (93.9; 99.3) 41.5 (34.3; 50.2) 100 (97.8; 100)
Day 42 155 99.4 (96.5; 100) 63.0 (52.2; 76.1) 100 (97.6; 100)
Month 6 156 92.3 (86.9; 96.0) 22.0 (18.5; 26.1) 96.8 (92.7; 99.0)
Month 12 144 75.7 (67.9; 82.4) 11.0 (9.2; 13.2) 84.0 (77.0; 89.6)
N number of subjects with available results (for seroconversion rate and seroconversion factor, N - the number of subjects with pre- and post-vaccination results
available), % - percentage of subjects; 95% CI - 95% confidence interval; Seroconversion: For initially seronegative subjects (i.e., HI titres <1:10), antibody titre ≥
1:40 after vaccination. For initially seropositive subjects, post-vaccination HI titre ≥ 4 fold the pre-vaccination antibody titre. Seroconversion Factor -mean[log10
(post-vaccination GMT/pre vaccination GMT)]; Pre = prior to vaccination, Day 21 etc- 21 days post vaccination. CBER Criteria were fulfilled if: the lower limit of the
95% CI for SCR was >40%, and the lower limit of the 95% CI for % ≥1:40 was >70%. CHMP Criteria were fulfilled if: the point estimate for SCR was > 40% and, the
post-vaccination point estimate for % ≥1:40 was >70% and, the point estimate for SCF was > 2.5. See Table 1 for details of treatment groups.
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Safety
The incidences of local and general solicited symptoms
were generally comparable in each study across the
study groups (Figures 3 and 4). Symptoms of grade 3 in-
tensity were reported by not more than 3.6% of adults in
each study group, and by not more than 6.5% of children
in each age subgroup. The point estimates for each
solicited local and general symptom tended to be lower
in the Q-Pan1.9 group than the 2 groups who received
0.9 μg of vaccine antigen, although the 95% CIs over-
lapped in all cases.
Other (unsolicited) adverse events occurring until
63 days following dose 2 were reported by 80 adults in
the Q-Pan group (24.2%; 95% CI 19.7, 29.2) and 86 in
the D-Pan group (26.1%; 95% CI 21.5, 31.2). Of these,
adverse events that were considered by the investigator
to be causally related to vaccination were reported by 20
adults (12%) in each treatment group. Most were reactions
Table 5 Study in children: haemagglutinin inhibition (HI) antibodies to A/California/7/2009 (H1N1)v-like strain after
vaccination (ATP cohorts for immunogenicity and persistence)
Group Time Seroconversion rate Seroconversion factor Seroprotection rate
point N % (95% CI) N Ratio (95% CI) N % ≥1:40 (95% CI)
Q-Pan0.9 Pre - - - - - - 76 36.8 (26.1; 48.7)
Day 21 76 98.7 (92.9; 100) 76 25.7 (20.7; 32.0) 76 98.7 (92.9; 100)
Month 6 73 63.0 (50.9; 74.0) 73 6.6 (5.4; 8.2) 73 75.3 (63.9; 84.7)
D-Pan0.9 Pre - - - - - - 75 32.0 (21.7; 43.8)
Day 21 75 98.7 (92.8; 100) 75 27.1 (22.4; 32.8) 75 98.7 (92.8; 100)
Month 6 74 71.6 (59.9; 81.5) 74 8.0 (6.4; 10.1) 74 85.1 (75.0; 92.3)
Q-Pan1.9 Pre - - - - - - 58 31.0 (19.5; 44.5)
Day 21 58 98.3 (90.8; 100) 58 32.2 (24.7; 42.0) 58 98.3 (90.8; 100)
Month 6 58 69.0 (55.5; 80.5) 58 8.9 (6.8; 11.7) 58 79.3 (66.6; 88.8)
N number of subjects with available results (for seroconversion rate and seroconversion factor N - the number of subjects with pre- and post-vaccination results
available); % - percentage of subjects; 95% CI - 95% confidence interval. Seroconversion: For initially seronegative subjects (i.e., HI titres <1:10), antibody titre≥
1:40 after vaccination. For initially seropositive subjects, antibody titre after vaccination ≥ 4 fold the pre-vaccination antibody titre. Seroconversion Factor -
Geometric Mean Ratio (mean[log10(post-vaccination GMT/pre vaccination GMT]). Pre - prior to vaccination, Day 21 etc- 21 days post vaccination. CBER Criteria
were fulfilled if: the lower limit of the 95% CI for SCR was >40%, and the lower limit of the 95% CI for % ≥1:40 was > 70%. CHMP Criteria were fulfilled if: the point
estimate for SCR was > 40% and, the post-vaccination point estimate for % ≥1:40 was > 70% and, the point estimate for SCF was >2.5. See Table 1 for details of
treatment groups.
Figure 2 Reverse cumulative curves of haemagglutinin inhibition (HI) antibody titres in adults and children (ATP immunogenicity
cohorts for each time point). See Table 1 for details of treatment groups in each study.
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at the injection site. In children, unsolicited adverse events
until day 42 post-vaccination were reported by 28 subjects
in the Q-Pan0.9 group (36.8%; 95% CI 26.1, 48.7), 28 sub-
jects in the D-Pan0.9 group (37.3%; 95% CI 26.4, 49.3) and
by 23 subjects in the Q-Pan1.9 group (39.7%; 95% CI 27.0,
53.4). Of these, adverse events reported by two subjects
each in the Q-Pan0.9 and D-Pan0.9 groups (2.6% and
2.7%, respectively) were considered vaccine-related. No
vaccine-related adverse events were reported in the Q-
Pan1.9 group.
Twenty SAEs (11 in the Q-Pan group, 9 in the D-Pan
group) were reported in the adult study up to Month 12.
The events were diverse and classified under 13 MedDRA
(Medical Dictionary for Regulatory Activities) system
organ classes. None were considered to be related to vac-
cination. One subject in the adult study developed a pIMD:
Bells palsy with onset 179 days after the second dose. The
event was considered unrelated to vaccination.
Two SAEs were reported in children up to Month 6
(dengue haemorrhagic fever and influenza type B). Nei-
ther event was considered to be related to vaccination.
No pIMDs were reported during the study period.
Discussion
Achieving sufficient production to supply vaccine glo-
bally during an influenza pandemic remains an objective
of the WHO and of vaccine manufacturers. In the present
studies immunological equivalence was demonstrated
Figure 3 Local and general solicited symptoms in adults. Total vaccinated cohort within 7 days after dose 1 (A) and dose 2 (B). Vertical lines
show 95% CIs. Grade 3 was defined as: pain -significant pain at rest, prevented normal activities as assessed by inability to attend/do work or
school: redness or swelling >100 mm; Fever: oral/axillary temperature ≥39.0°C; all other symptoms: Prevents normal everyday activities as
assessed by inability to attend/do work or school, or requires intervention of a physician/healthcare provider. See Table 1 for details of treatment
groups in each study.
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between A/California/7/2009 (H1N1)v-like HA manu-
factured at two manufacturing sites when adjuvanted
with AS03 in two populations (adults and children), and
at two doses (standard dose in adults and low dose
in children). These data allow for increased flexibility in
vaccine supply in response to a pandemic, and add to re-
ports of immunogenicity equivalence for D-Pan and Q-Pan
H5N1 vaccines [12] and the use of GlaxoSmithKline’s AS03
adjuvant system with Sanofi Pasteur’sH1N1 antigen [18].
The recommended paediatric dose of A/California/7/
2009 (H1N1)v-like-AS03 vaccine is half the antigen and
adjuvant content of the adult dose. This study showed
that reducing the HA dose further, to one-quarter of the
adult dose adjuvanted with AS03B, resulted in robust
immune response that fulfilled all CBER and CHMP
criteria in children. Antibody persistence 6 months
after vaccination was similar in all children, regardless
of antigen dose administered. These data suggest that
there may be scope to further reduce the paediatric H1N1
dose, allowing further antigen sparing (16-fold for children
3 years of age or older). These data also suggest that chan-
ging end-of-shelf-life specifications such that vaccine at
expiry contains one-half the recommended antigen dose,
is unlikely to impact clinical potency, but would allow for
the extended use of available vaccine stocks.
The results of these studies are consistent with pre-
viously published data of A/California/7/2009 (H1N1)v-
like-AS03 in adults and children [5-8,19]. Notably, a single
vaccine dose was highly immunogenic in both age groups,
confirming recommendations for one dose across all ages.
Figure 4 Local and general solicited symptoms in children. Total vaccinated cohort within 7 days after vaccination in children 3-<6 years (A)
and in children 6-9 years (B). Vertical lines show 95% CIs. Grade 3 was defined as: pain - cries when limb is moved/spontaneously painful; redness
or swelling >100 mm; Fever: oral/axillary temperature ≥39.0°C; In addition, in children 3- < 6 years: Irritability - crying that cannot be comforted/
prevents normal activity; Drowsiness - prevents normal activity; Loss of appetite - not eating at all. In children 6-9 years: all other symptoms -
prevents normal activity. See Table 1 for details of treatment groups in each study.
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The reactogenicity and safety profile of A/California/7/
2009 (H1N1)v-like-AS03 manufactured in Dresden and
Quebec was consistent with the known reactogenicity pro-
file of A/California/7/2009 (H1N1)v-like vaccine adjuvanted
with AS03 in adults and children [3]. Reactogenicity was
not observed to increase after the second dose in adults.
Reports from epidemiological studies conducted in some
European countries indicated a 6- to 13-fold increased risk
of narcolepsy in children/adolescents vaccinated with
Pandemrix™ (D-Pan) as compared with unvaccinated indi-
viduals [20-22]. This risk increase has not been found in
adults (20 years and older). In the current studies no safety
concerns were identified during extended safety follow-up
for 6 months after vaccination in children and 12 months
in adults, and no cases of narcolepsy or Guillain-Barré syn-
drome were identified [23].
The present studies provide no data on the use of D-
Pan versus Q-Pan in the age group between 10 and
18 years, or in adults over 60 years of age. However,
good immunogenicity of A/California/7/2009 (H1N1)
v-AS03 vaccine manufactured in Quebec and Dresden
has been demonstrated in other studies for both age
groups [7,9,10,24-27].
Conclusions
Two studies indicate that A/California/7/2009 (H1N1)v-
like HA manufactured at two sites are immunologically
equivalent when administered with AS03, allowing flexi-
bility of supply during influenza pandemics. The studies
confirm the robust immunogenicity of A/California/7/
2009 (H1N1)v-like vaccine adjuvanted to AS03. The
possibility to further reduce the administered antigen
dose to children warrants additional investigation.
PANDEMRIX and AREPANRIX are trademarks of the
GlaxoSmithKline group of companies.
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